Tests Lumify eye drops for redness in people with glaucoma
Tests Lumify eye drops against saline in glaucoma patients already using brimonidine drops.
Plain-language title generated from the registry record
Registry title: The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
Key facts
- Where
- New Orleans, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Tulane University Medical CenterNew Orleans, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tulane University
- Trial code
- NCT04007276
- Record updated
- 13 October 2026
- Original description
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.Read full original descriptionShow less
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Inclusion: Age > 18 years; Diagnosis of primary open angle glaucoma; Willing and able to give informed consent; Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use.
Exclusion: No surgery within the past 6 months; Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study; Known allergy or sensitivities to brimonidine; No history of lid surgery or botox; Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator; Pregnancy; Prisoners; Inability to sit comfortably for 30 minutes.